Cite
HARVARD Citation
Loibl, S. et al. (2018). PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Annals of oncology. p. 2151. [Online].